Molecular therapeutics in breast cancer
1 – 25 of 25
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer
(
- Contribution to journal › Article
-
Mark
Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance
2024) In Molecular Oncology(
- Contribution to journal › Article
- 2023
-
Mark
Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
(
- Contribution to journal › Article
-
Mark
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
(
- Contribution to journal › Article
-
Mark
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer : a multidisciplinary expert consensus
(
- Contribution to journal › Scientific review
-
Mark
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
(
- Contribution to journal › Article
- 2022
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
(
- Contribution to journal › Article
-
Mark
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
(
- Contribution to journal › Article
-
Mark
An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
(
- Contribution to journal › Article
-
Mark
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
(
- Contribution to journal › Article
-
Mark
Molecular analyses of triple-negative breast cancer in the young and elderly
(
- Contribution to journal › Article
-
Mark
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
(
- Contribution to journal › Article
- 2020
-
Mark
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
(
- Contribution to journal › Article
-
Mark
Whole-genome sequencing of triple negative breast cancers in a standard population-based clinical setting
2020) UK Interdisciplinary Breast Cancer Symposium 2020 In Breast Cancer Research and Treatment 180. p.531-532(
- Contribution to journal › Published meeting abstract
- 2019
-
Mark
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
(
- Contribution to journal › Article
-
Mark
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma
(
- Contribution to journal › Article
- 2017
-
Mark
Strategies to design clinical studies to identify predictive biomarkers in cancer research
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Models of breast morphogenesis based on localization of stem cells in the developing mammary lobule
(
- Contribution to journal › Article
-
Mark
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells
(
- Contribution to journal › Article
-
Mark
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium
(
- Contribution to journal › Article
-
Mark
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
(
- Contribution to journal › Article
- 2013
-
Mark
A novel model of dormancy for bone metastatic breast cancer cells
(
- Contribution to journal › Article
-
Mark
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
(
- Contribution to journal › Article